Sirona Biochem Signs LOI With China's #1 Ranked Anti-Diabetic Company, Wanbang Pharma

VANCOUVER, BRITISH COLUMBIA--(Marketwired - Aug. 19, 2013) - Sirona Biochem Corp. (TSX VENTURE:SBM) (OTCQX:SRBCF) (FRANKFURT:ZSB) announced today the signing of a Letter of Intent whereby Sirona Biochem will provide an exclusive license to Wanbang Pharma to develop and commercialize Sirona's SGLT2 Inhibitor in the People's Republic of China (PRC). In exchange for this license, Sirona Biochem will receive upfront and milestone payments of up to US$9.5M upon successful achievement of development and regulatory milestones and then royalty payments for product sales in the PRC.

Under the terms of the LOI, Wanbang Pharma will assume responsibility for funding and leading all clinical studies required for Chinese Food and Drug Administration approval. Sirona Biochem will be provided all clinical study results to support new regulatory applications outside of PRC.

"We are excited by the opportunity to work with Wan bang Pharma, the leading anti-diabetic company supplying the largest diabetic population in the world," said Neil Belenkie, Chief Executive Officer of Sirona Biochem. "With more than 90 million people suffering from diabetes in China and the market growing more than 20% per year, we believe that Wanbang Pharma is uniquely positioned to provide maximum potential to commercialize our SGLT2 Inhibitor in the Chinese marketplace".

About Wanbang Pharma

Wanbang Biopharmaceuticals is a leading pharmaceutical company in China that specializes in research, production and marketing of medicines for diabetes, cardiovascular disease and endocrinology. Among domestic pharmaceutical companies, Wanbang Pharma is the largest manufacturer and marketer of a comprehensive portfolio of drugs for diabetes.

Wanbang Pharma is a subsidiary of Fosun Pharmaceutical Group which is listed on the Shanghai stock exchange (SHA:600196). Fosun Pharma, a major shareholder of Sino Pharma (HKG:1099), the largest drug distributor in China, is part of the Fosun Group, the largest non-state owned enterprise group in China which is listed on the Hong Kong stock exchange (HKG:0656).

About Sirona Biochem

Sirona Biochem is a biotechnology company developing diabetes therapeutics, skin depigmenting and anti-aging agents for cosmetic use, biological ingredients and cancer vaccine antigens. The company utilizes a proprietary chemistry technique to improve pharmaceutical properties of carbohydrate-based molecules. Sirona Biochem is the parent company of French-based biotechnology company, TFChem. For more information visit www.sironabiochem.com.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

This news release contains forward-looking information, which involves known and unknown risks, uncertainties and other factors that may cause actual events to differ materially from current expectation. Forward-looking statements in many case can be identified by words such as "may", "will", "expect", "believe", "potential" or other similar terms. Risks and uncertainties include, without limitation, negotiation of the terms of a definitive licence agreement; difficulties or delays in development, testing and obtaining regulatory approval of a drug; unexpected adverse side effects or inadequate therapeutic efficacy of a drug that could delay or prevent product development or commercialization; the scope and validity of patent protection for a product; and competition from other pharmaceutical or biotechnology companies. As a result, there are no assurances (i) that Sirona Biochem will be able to enter into a definitive license agreement with Wanbang Pharma or that it will be completed on the terms set out in the LOI; (ii) that Wanbang Pharma will be able to develop and commercialize Sirona's SGLT2 Inhibitor or obtain China's FDA approval of a drug; and (iii) that Sirona Biochem will be able to earn the milestone payments as contemplated under the LOI or Wanbang Pharma will obtain sales of a drug at reasonable commercial levels.

Readers are accordingly cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this news release. Sirona Biochem does not assume any obligation to update any forward-looking statements except as required by law.